Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
7.90
+0.96 (13.83%)
At close: May 28, 2025, 4:00 PM
7.89
-0.01 (-0.13%)
After-hours: May 28, 2025, 4:38 PM EDT
Ocular Therapeutix Stock Forecast
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for Ocular Therapeutix stock ranges from a low of $11 to a high of $22. The average analyst price target of $16.11 forecasts a 103.92% increase in the stock price over the next year.
Price Target: $16.11 (+103.92%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ocular Therapeutix stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 5 | 5 | 5 | 6 | 7 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $15 → $14 | Strong Buy | Maintains | $15 → $14 | +77.22% | May 6, 2025 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Apr 8, 2025 |
| Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +89.87% | Apr 8, 2025 |
| RBC Capital | RBC Capital | Buy Initiates $17 | Buy | Initiates | $17 | +115.19% | Mar 18, 2025 |
| Needham | Needham | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +89.87% | Mar 11, 2025 |
Financial Forecast
Revenue This Year
56.41M
from 63.72M
Decreased by -11.48%
Revenue Next Year
63.96M
from 56.41M
Increased by 13.38%
EPS This Year
-1.45
from -1.22
EPS Next Year
-1.47
from -1.45
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 72.8M | 77.6M | 219.1M | ||
| Avg | 56.4M | 64.0M | 118.6M | ||
| Low | 48.9M | 51.3M | 64.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 14.2% | 37.6% | 242.6% | ||
| Avg | -11.5% | 13.4% | 85.4% | ||
| Low | -23.3% | -9.1% | 0.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.25 | -1.34 | -0.42 | ||
| Avg | -1.45 | -1.47 | -1.18 | ||
| Low | -1.49 | -1.54 | -1.51 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.